Eliem Therapeutics (ELYM) Competitors

$11.00 +0.09 (+0.82%)

As of 05/22/2026

ELYM vs. OLMA, HROW, DBVT, COLL, and MRVI

Should you buy Eliem Therapeutics stock or one of its competitors? MarketBeat compares Eliem Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Eliem Therapeutics include Olema Pharmaceuticals (OLMA), Harrow (HROW), DBV Technologies (DBVT), Collegium Pharmaceutical (COLL), and Maravai LifeSciences (MRVI). These companies are all part of the "pharmaceutical products" industry.

How does Eliem Therapeutics compare to Olema Pharmaceuticals?

Olema Pharmaceuticals (NASDAQ:OLMA) and Eliem Therapeutics (NASDAQ:ELYM) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, analyst recommendations, profitability, institutional ownership, dividends, media sentiment and valuation.

Eliem Therapeutics is trading at a lower price-to-earnings ratio than Olema Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Olema Pharmaceuticals	N/A	N/A	-$162.45M	-$2.02	N/A
Eliem Therapeutics	N/A	N/A	-$35.12M	-$0.53	N/A

Olema Pharmaceuticals' return on equity of -46.00% beat Eliem Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Olema Pharmaceuticals	N/A	-46.00%	-41.22%
Eliem Therapeutics	N/A	-47.03%	-45.97%

Olema Pharmaceuticals presently has a consensus price target of $44.10, suggesting a potential upside of 222.37%. Given Olema Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts plainly believe Olema Pharmaceuticals is more favorable than Eliem Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Olema Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71
Eliem Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

91.8% of Olema Pharmaceuticals shares are owned by institutional investors. Comparatively, 69.8% of Eliem Therapeutics shares are owned by institutional investors. 12.6% of Olema Pharmaceuticals shares are owned by company insiders. Comparatively, 4.7% of Eliem Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Olema Pharmaceuticals has a beta of 2.05, suggesting that its share price is 105% more volatile than the broader market. Comparatively, Eliem Therapeutics has a beta of -0.39, suggesting that its share price is 139% less volatile than the broader market.

In the previous week, Olema Pharmaceuticals had 7 more articles in the media than Eliem Therapeutics. MarketBeat recorded 8 mentions for Olema Pharmaceuticals and 1 mentions for Eliem Therapeutics. Eliem Therapeutics' average media sentiment score of 0.88 beat Olema Pharmaceuticals' score of 0.19 indicating that Eliem Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Olema Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Eliem Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Olema Pharmaceuticals beats Eliem Therapeutics on 10 of the 13 factors compared between the two stocks.

How does Eliem Therapeutics compare to Harrow?

Eliem Therapeutics (NASDAQ:ELYM) and Harrow (NASDAQ:HROW) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, earnings, media sentiment, risk, institutional ownership, valuation and profitability.

Eliem Therapeutics has a beta of -0.39, meaning that its share price is 139% less volatile than the broader market. Comparatively, Harrow has a beta of 0.34, meaning that its share price is 66% less volatile than the broader market.

Harrow has higher revenue and earnings than Eliem Therapeutics. Harrow is trading at a lower price-to-earnings ratio than Eliem Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eliem Therapeutics	N/A	N/A	-$35.12M	-$0.53	N/A
Harrow	$272.30M	4.52	-$5.14M	-$0.41	N/A

In the previous week, Harrow had 12 more articles in the media than Eliem Therapeutics. MarketBeat recorded 13 mentions for Harrow and 1 mentions for Eliem Therapeutics. Eliem Therapeutics' average media sentiment score of 0.88 beat Harrow's score of 0.70 indicating that Eliem Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eliem Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Harrow	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

69.8% of Eliem Therapeutics shares are held by institutional investors. Comparatively, 72.8% of Harrow shares are held by institutional investors. 4.7% of Eliem Therapeutics shares are held by insiders. Comparatively, 12.8% of Harrow shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Eliem Therapeutics has a net margin of 0.00% compared to Harrow's net margin of -5.57%. Harrow's return on equity of 19.59% beat Eliem Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eliem Therapeutics	N/A	-47.03%	-45.97%
Harrow	-5.57%	19.59%	2.26%

Harrow has a consensus price target of $69.43, indicating a potential upside of 110.39%. Given Harrow's stronger consensus rating and higher possible upside, analysts clearly believe Harrow is more favorable than Eliem Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eliem Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Harrow	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64

Summary

Harrow beats Eliem Therapeutics on 12 of the 15 factors compared between the two stocks.

How does Eliem Therapeutics compare to DBV Technologies?

Eliem Therapeutics (NASDAQ:ELYM) and DBV Technologies (NASDAQ:DBVT) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, institutional ownership, analyst recommendations, media sentiment, earnings, profitability, valuation and dividends.

DBV Technologies has a consensus target price of $40.25, suggesting a potential upside of 121.40%. Given DBV Technologies' stronger consensus rating and higher probable upside, analysts clearly believe DBV Technologies is more favorable than Eliem Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eliem Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
DBV Technologies	2 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.67

Eliem Therapeutics has a net margin of 0.00% compared to DBV Technologies' net margin of -2,895.37%. Eliem Therapeutics' return on equity of -47.03% beat DBV Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eliem Therapeutics	N/A	-47.03%	-45.97%
DBV Technologies	-2,895.37%	-129.88%	-88.84%

69.8% of Eliem Therapeutics shares are held by institutional investors. Comparatively, 71.7% of DBV Technologies shares are held by institutional investors. 4.7% of Eliem Therapeutics shares are held by company insiders. Comparatively, 1.1% of DBV Technologies shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Eliem Therapeutics has higher earnings, but lower revenue than DBV Technologies. Eliem Therapeutics is trading at a lower price-to-earnings ratio than DBV Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eliem Therapeutics	N/A	N/A	-$35.12M	-$0.53	N/A
DBV Technologies	$5.64M	190.86	-$146.95M	-$4.46	N/A

In the previous week, DBV Technologies had 1 more articles in the media than Eliem Therapeutics. MarketBeat recorded 2 mentions for DBV Technologies and 1 mentions for Eliem Therapeutics. Eliem Therapeutics' average media sentiment score of 0.88 beat DBV Technologies' score of 0.00 indicating that Eliem Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eliem Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
DBV Technologies	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Eliem Therapeutics has a beta of -0.39, suggesting that its stock price is 139% less volatile than the broader market. Comparatively, DBV Technologies has a beta of -0.96, suggesting that its stock price is 196% less volatile than the broader market.

Summary

Eliem Therapeutics and DBV Technologies tied by winning 8 of the 16 factors compared between the two stocks.

How does Eliem Therapeutics compare to Collegium Pharmaceutical?

Eliem Therapeutics (NASDAQ:ELYM) and Collegium Pharmaceutical (NASDAQ:COLL) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, dividends, earnings, profitability, risk and valuation.

Collegium Pharmaceutical has a net margin of 9.41% compared to Eliem Therapeutics' net margin of 0.00%. Collegium Pharmaceutical's return on equity of 95.18% beat Eliem Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eliem Therapeutics	N/A	-47.03%	-45.97%
Collegium Pharmaceutical	9.41%	95.18%	16.39%

Eliem Therapeutics has a beta of -0.39, suggesting that its share price is 139% less volatile than the broader market. Comparatively, Collegium Pharmaceutical has a beta of 0.76, suggesting that its share price is 24% less volatile than the broader market.

Collegium Pharmaceutical has higher revenue and earnings than Eliem Therapeutics. Eliem Therapeutics is trading at a lower price-to-earnings ratio than Collegium Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eliem Therapeutics	N/A	N/A	-$35.12M	-$0.53	N/A
Collegium Pharmaceutical	$780.57M	1.42	$62.87M	$2.04	16.70

In the previous week, Collegium Pharmaceutical had 1 more articles in the media than Eliem Therapeutics. MarketBeat recorded 2 mentions for Collegium Pharmaceutical and 1 mentions for Eliem Therapeutics. Eliem Therapeutics' average media sentiment score of 0.88 beat Collegium Pharmaceutical's score of 0.65 indicating that Eliem Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eliem Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Collegium Pharmaceutical	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

69.8% of Eliem Therapeutics shares are held by institutional investors. 4.7% of Eliem Therapeutics shares are held by insiders. Comparatively, 1.9% of Collegium Pharmaceutical shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Collegium Pharmaceutical has a consensus price target of $57.50, suggesting a potential upside of 68.77%. Given Collegium Pharmaceutical's stronger consensus rating and higher probable upside, analysts plainly believe Collegium Pharmaceutical is more favorable than Eliem Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eliem Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Collegium Pharmaceutical	0 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.67

Summary

Collegium Pharmaceutical beats Eliem Therapeutics on 12 of the 15 factors compared between the two stocks.

How does Eliem Therapeutics compare to Maravai LifeSciences?

Maravai LifeSciences (NASDAQ:MRVI) and Eliem Therapeutics (NASDAQ:ELYM) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, earnings, valuation, media sentiment, analyst recommendations, dividends, risk and institutional ownership.

Maravai LifeSciences presently has a consensus price target of $5.50, indicating a potential upside of 25.00%. Given Maravai LifeSciences' stronger consensus rating and higher possible upside, equities research analysts clearly believe Maravai LifeSciences is more favorable than Eliem Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Maravai LifeSciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Eliem Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Eliem Therapeutics has a net margin of 0.00% compared to Maravai LifeSciences' net margin of -51.07%. Maravai LifeSciences' return on equity of -17.87% beat Eliem Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Maravai LifeSciences	-51.07%	-17.87%	-9.08%
Eliem Therapeutics	N/A	-47.03%	-45.97%

Maravai LifeSciences has a beta of 0.62, indicating that its share price is 38% less volatile than the broader market. Comparatively, Eliem Therapeutics has a beta of -0.39, indicating that its share price is 139% less volatile than the broader market.

Eliem Therapeutics has lower revenue, but higher earnings than Maravai LifeSciences. Eliem Therapeutics is trading at a lower price-to-earnings ratio than Maravai LifeSciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Maravai LifeSciences	$185.74M	6.12	-$130.77M	-$0.71	N/A
Eliem Therapeutics	N/A	N/A	-$35.12M	-$0.53	N/A

In the previous week, Maravai LifeSciences and Maravai LifeSciences both had 1 articles in the media. Eliem Therapeutics' average media sentiment score of 0.88 beat Maravai LifeSciences' score of 0.64 indicating that Eliem Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Maravai LifeSciences	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Eliem Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

50.3% of Maravai LifeSciences shares are held by institutional investors. Comparatively, 69.8% of Eliem Therapeutics shares are held by institutional investors. 2.5% of Maravai LifeSciences shares are held by company insiders. Comparatively, 4.7% of Eliem Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Maravai LifeSciences beats Eliem Therapeutics on 8 of the 14 factors compared between the two stocks.

Get Eliem Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ELYM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ELYM vs. The Competition

Export

Metric	Eliem Therapeutics	Pharmaceutical Industry	Medical Sector	NASDAQ Exchange
Market Cap	$327.27M	$927.43M	$6.46B	$12.34B
Dividend Yield	N/A	4.84%	2.76%	5.28%
P/E Ratio	-20.75	1.46	21.21	25.65
Price / Sales	N/A	119.63	554.38	86.31
Price / Cash	N/A	20.07	43.49	56.67
Price / Book	2.82	7.59	10.37	7.14
Net Income	-$35.12M	-$3.64M	$3.57B	$335.98M
7 Day Performance	1.85%	3.01%	6.40%	4.15%
1 Month Performance	20.35%	76.62%	3.53%	2.54%
1 Year Performance	832.20%	126.61%	34.04%	35.06%

Eliem Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ELYM Eliem Therapeutics	N/A	$11.00 +0.8%	N/A	+832.2%	$327.27M	N/A	N/A	9
OLMA Olema Pharmaceuticals	2.5273 of 5 stars	$13.96 +6.6%	$44.10 +215.9%	+171.4%	$1.14B	N/A	N/A	70
HROW Harrow	4.5143 of 5 stars	$30.86 +0.6%	$69.43 +125.0%	+27.4%	$1.14B	$272.30M	N/A	180
DBVT DBV Technologies	2.2033 of 5 stars	$18.54 +0.2%	$40.25 +117.1%	+116.2%	$1.10B	$5.64M	N/A	80	Gap Up
COLL Collegium Pharmaceutical	2.9549 of 5 stars	$34.22 +1.8%	$57.50 +68.0%	+18.1%	$1.09B	$780.57M	16.77	210

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ELYM) was last updated on 5/26/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Eliem Therapeutics (ELYM) Competitors

ELYM vs. OLMA, HROW, DBVT, COLL, and MRVI

How does Eliem Therapeutics compare to Olema Pharmaceuticals?

Summary

How does Eliem Therapeutics compare to Harrow?

Summary

How does Eliem Therapeutics compare to DBV Technologies?

Summary

How does Eliem Therapeutics compare to Collegium Pharmaceutical?

Summary

How does Eliem Therapeutics compare to Maravai LifeSciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ELYM vs. The Competition

Eliem Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Eliem Therapeutics (ELYM) Competitors

ELYM vs. OLMA, HROW, DBVT, COLL, and MRVI

How does Eliem Therapeutics compare to Olema Pharmaceuticals?

Which has preferable earnings and valuation, OLMA or ELYM?

Is OLMA or ELYM more profitable?

Do analysts prefer OLMA or ELYM?

Do insiders and institutionals hold more shares of OLMA or ELYM?

Which has more risk and volatility, OLMA or ELYM?

Does the media favor OLMA or ELYM?

Summary

How does Eliem Therapeutics compare to Harrow?

Which has more risk and volatility, ELYM or HROW?

Which has stronger valuation and earnings, ELYM or HROW?

Does the media favor ELYM or HROW?

Do institutionals and insiders have more ownership in ELYM or HROW?

Is ELYM or HROW more profitable?

Do analysts recommend ELYM or HROW?

Summary

How does Eliem Therapeutics compare to DBV Technologies?

Do analysts recommend ELYM or DBVT?

Is ELYM or DBVT more profitable?

Do institutionals & insiders believe in ELYM or DBVT?

Which has stronger valuation and earnings, ELYM or DBVT?

Does the media refer more to ELYM or DBVT?

Which has more risk & volatility, ELYM or DBVT?

Summary

How does Eliem Therapeutics compare to Collegium Pharmaceutical?

Is ELYM or COLL more profitable?

Which has more volatility & risk, ELYM or COLL?

Which has better earnings & valuation, ELYM or COLL?

Does the media prefer ELYM or COLL?

Do insiders & institutionals believe in ELYM or COLL?

Do analysts recommend ELYM or COLL?

Summary

How does Eliem Therapeutics compare to Maravai LifeSciences?

Do analysts rate MRVI or ELYM?

Is MRVI or ELYM more profitable?

Which has more risk & volatility, MRVI or ELYM?

Which has higher valuation and earnings, MRVI or ELYM?

Does the media favor MRVI or ELYM?

Do insiders and institutionals have more ownership in MRVI or ELYM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ELYM vs. The Competition

Eliem Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools